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The restriction factors, TRIM5α in most primates and TRIMCyp in owl monkeys, block infection of various retroviruses soon after virus entry
into the host cell. Rhesus monkey TRIM5α (TRIM5αrh) inhibits human immunodeficiency virus (HIV-1) and feline immunodeficiency virus
(FIV) more potently than human TRIM5α (TRIM5αhu). TRIMCyp restricts infection of HIV-1, simian immunodeficiency virus of African green
monkeys (SIVagm) and FIV. Early after infection, TRIMCyp, like TRIM5αrh and TRIM5αhu, decreased the amount of particulate viral capsid in
the cytosol of infected cells. The requirements for the TRIMCyp and TRIM5α domains in restricting different retroviruses were investigated.
Potent restriction of FIV by TRIMCyp occurred in the complete absence of RING and B-box 2 domains; by contrast, efficient FIV restriction by
TRIM5αrh required these domains. Variable region 1 of the TRIM5αrh B30.2 domain contributed to the potency of HIV-1, FIV and equine
infectious anemia virus restriction. Thus, although differences exist in the requirements of TRIMCyp and TRIM5α for RING/B-box 2 domains,
both restriction factors exhibit mechanistic similarities.
© 2007 Elsevier Inc. All rights reserved.Keywords: Restriction factors; Retrovirus; Uncoating; Human immunodeficiency virusIntroduction
Following entry into cells, some retroviruses encounter
dominant blocks to infection that act prior to reverse trans-
cription (Cowan et al., 2002; Munk et al., 2002). For example,
human immunodeficiency virus (HIV-1) is blocked in the cells
of most OldWorldmonkeys (Hofmann et al., 1999). Infection by
the simian immunodeficiency virus of macaques (SIVmac)
encounters similar restrictions in New World monkeys (Hof-
mann et al., 1999). These restrictions are mediated by TRIM5α,
a tripartite motif protein with a RING, B-box 2 and coiled-coil
(CC) domain, as well as a carboxy-terminal B30.2(SPRY)⁎ Corresponding author. Dana-Farber Cancer Institute, 44 Binney Street – JFB
824, Boston, MA 02115, USA. Fax: +1 671 632 4338.
E-mail address: joseph_sodroski@dfci.harvard.edu (J. Sodroski).
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doi:10.1016/j.virol.2007.08.032domain (Stremlau et al., 2004; Song et al., 2005b). The TRIM5α
B30.2 domain is essential for retroviral restriction, and
differences in the potency of TRIM5α from different species
map to this domain (Sawyer et al., 2005; Stremlau et al., 2005;
Yap et al., 2005). In addition to inhibiting HIV-1, TRIM5αrh
potently restricts feline immunodeficiency virus (FIV) and
equine infectious anemia virus (EIAV) infections (Hatziioannou
et al., 2004; Keckesova et al., 2004; Olsen, 1998; Saenz et al.,
2005).
Owlmonkeys are an unusual NewWorldmonkey species that
exhibit restrictions to HIV-1 and not SIVmac infection (Hofmann
et al., 1999; Towers et al., 2003). Instead of TRIM5α, owl
monkeys express TRIMCyp, a protein that consists of the RING,
B-box 2 and CC domains of TRIM5 fused with a carboxy-
terminal cyclophilin A (Cyp A) moiety (Nisole et al., 2004;
Sayah et al., 2004; Ribeiro et al., 2005). The TRIMCyp gene was
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Cyp A genes. Cyp A is known to bind a surface-exposed loop on
the HIV-1 p24 capsid protein (Gamble et al., 1996; Luban et al.,
1993). Besides restricting HIV-1 infection, TRIMCyp also
potently inhibits infection by FIV and SIVagm (Diaz-Griffero
et al., 2006b; Lin and Emerman, 2006).
The viral determinant of susceptibility to TRIM5α- and
TRIMCyp-mediated restriction is the capsid protein, which as-
sembles into the capsid structure that surrounds the viral genomic
RNA and enzymes (Owens et al., 2004, 2003). Studies following
the fate of the HIV-1 andN-MLV capsids in the cytoplasm of cells
expressing TRIM5αrh or TRIM5αhu, respectively, established a
correlation between restriction and the premature conversion of
particulate capsids to soluble capsid proteins (Perron et al., 2007;
Stremlau et al., 2006). However, the effect of TRIMCyp on the
fate of restricted retroviral capsids is not known.
Here we investigate the requirements for retroviral restriction
by TRIM5αrh and TRIMCyp. Like TRIM5αrh, TRIMCypFig. 1 (continued ).
Fig. 1. Fate of the HIV-1 capsid in the cytosol of cells expressing TRIM5αrh and
TRIMCyp. Cf2Th (A, C, D) or CRFK (B) cells transduced with TRIMCyp,
TRIMCypΔ128, TRIMCyp R120E, TRIM5αrh or the empty LPCX control
vector were incubated with either VSV G-pseudotyped (Env+) HIV-1 or
envelope-deficient (Env−) HIV-1 for 16 h in the presence or absence of 10 μM
MG115. Cytoplasmic lysates were analyzed directly (“Input”) or were separated
on a sucrose gradient into soluble and particulate fractions. The particulate
fractions (“Pellet”) were analyzed by Western blot using an antibody directed
against the HIV-1 p24 capsid protein. In E, Cf2Th cells expressing TRIM5αrh
and TRIMCyp were treated for 16 h with either DMSO or 10 μM MG115. The
cells were then fixed and stained with an antibody directed against the HA
epitope tag.decreased the amount of particulate capsid in the cytosol
following HIV-1 infection. As TRIMCyp and TRIM5αrh
potently restrict FIV infection, we determined the contribution
of each TRIM domain to this restriction. FIV restriction by
TRIMCyp did not require the RING and B-box 2 domains for
full potency. In contrast, TRIM5αrh required the RING and B-
box 2 sequences to achieve efficient restriction of FIV. Studies
using human–monkey TRIM5α chimerae demonstrated that the
variable region 1 of the B30.2 domain contains potency
determinants for FIV restriction.
Results
Effect of TRIMCyp on the amount of particulate capsid during
HIV-1 infection
Both TRIM5αrh and TRIMCyp potently restrict HIV-1
infection. The expression of TRIM5αrh in target cells results in
a decrease in the amount of particulate cytosolic capsids during
HIV-1 infection (Stremlau et al., 2006). To test the effect of
TRIMCyp on the integrity of HIV-1 capsid complexes in the
cytosol of infected cells, we studied the fate of the HIV-1 capsid
in Cf2Th canine thymocytes expressing TRIMCyp and
TRIM5αrh. As shown in Fig. 1A, expression of TRIMCyp
Fig. 2. Time course of TRIMCyp-induced loss of particulate HIV-1 capsids in
infected cells. Cf2Th cells transduced with either an empty LPCX vector or an
LPCX vector expressing TRIMCyp were incubated at 4 °C for 30 min with
either HIV-1 Env+ or Env− virus-like particles. Cells were then incubated at
37 °C for the indicated times and lysed. Cytoplasmic lysates were analyzed
directly (“Input”) or were separated on a sucrose gradient into soluble and
particulate fractions. The particulate fractions (“Pellet”) were Western blotted
using an antibody directed against the HIV-1 p24 protein.
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with that in cells transduced with the empty LPCX vector. The
decrease in the amount of particulate HIV-1 capsid in the
cytosol of cells expressing TRIMCyp was comparable to that
observed as a result of TRIM5αrh expression. No cytosolic
capsid was detected in cells challenged with HIV-1 particles
lacking envelope glycoproteins. Similar results were obtained
after HIV-1 challenge of CRFK feline cells expressing
TRIMCyp and TRIM5αrh (Fig. 1B). Deletion of the TRIMCyp
RING and B-box 2 domains (TRIMCypΔ128) or alteration of
the TRIMCyp B-box 2 domain (TRIMCyp R120E) abrogated
the TRIMCyp-mediated decrease in the level of cytosolic,
particulate capsids (Fig. 1C, upper panel). These observations
suggest that the expression of TRIMCyp, like that of TRIM5αrh
(Stremlau et al., 2006), results in a decrease in the amount of
particulate capsid in the cytosol of HIV-1-infected cells.
Proteasome inhibition does not affect the efficiency of
TRIM5αrh-mediated restriction of HIV-1 (Perez-Caballero et al.,
2005b; Stremlau et al., 2006), but has been reported to rescue the
production of viral reverse transcripts in cells expressing a
restricting TRIM5α protein (Anderson et al., 2006; Wu et al.,
2006). We examined the effects of proteasome inhibition on the
TRIM5αrh- and TRIMCyp-mediated decrease in the level of
particulate, cytosolic HIV-1 capsids in infected cells. Target cells
expressing TRIM5αrh or TRIMCyp, or control cells transduced
with the empty LPCX vector, were treated with the proteasome
inhibitor MG115 throughout the period of exposure to HIV-1. In
the control cells as well as the cells expressing TRIM5αrh or
TRIMCyp, a dramatic increase in the amount of pelletable
cytosolic HIV-1 capsid was observed after MG115 treatment
(Figs. 1C and D). No significant differences were observed
between the amounts of cytosolic, pelletable capsid in the
control or TRIM5αrh/TRIMCyp-expressing cells in the presence
of MG115. Thus, proteasome inhibition results in a general
increase in the amount of particulate capsids in the cytosol of
HIV-1-infected cells.
To examine the effect of proteasome inhibition on the intra-
cellular distribution of the TRIM5αrh and TRIMCyp proteins,
cells stably expressing these proteins were treated with MG115
or the DMSO solvent. The cells were then stained with an
antibody directed against the hemagglutinin (HA) epitope tag on
the TRIM5αrh and TRIMCyp proteins. In the cells treated with
the DMSO solvent, TRIM5αrh and TRIMCyp exhibited diffuse
cytoplasmic staining punctuated by cytoplasmic speckles
(Fig. 1E). By contrast, the TRIM5αrh and TRIMCyp proteins
in theMG115-treated cells coalesced into large inclusion bodies.
These results are consistent with previous observations sug-
gesting that proteasome inhibition leads to the movement of
TRIM5α into pre-aggresomal cytoplasmic bodies (Diaz-Grif-
fero et al., 2006a).
Timing of the TRIMCyp effect on particulate cytosolic HIV-1
capsids
The owl monkey TRIMCyp protein acts to restrict HIV-1
infection within the first hour following virus entry (Diaz-
Griffero et al., 2006b; Perez-Caballero et al., 2005b). To exa-mine the kinetics of the TRIMCyp-mediated decrease in
cytosolic levels of particulate capsid, we challenged control
cells or TRIMCyp-expressing cells with HIV-1 pseudotyped
with the VSV-G envelope glycoprotein and followed the
amount of particulate capsid over a 48-h period. At all time
points examined, the amount of particulate capsid in TRIMCyp-
expressing cells was less than that seen in the LPCX-transduced
control cells (Fig. 2). No capsid protein was observed in cell
lysates prepared 16 h after challenge of TRIMCyp-expressing
or LPCX-transduced cells with HIV-1 lacking envelope
glycoproteins. Thus, the amount of pelletable capsid in the
cytosol of LPCX-transduced cells is greater than that in
TRIMCyp-expressing cells at multiple time points after HIV-1
infection.
TRIMCyp domains involved in the restriction of feline
immunodeficiency virus (FIV) infection
Owl monkey TRIMCyp blocks FIVand SIVagm infection in
addition to that of HIV-1 (Diaz-Griffero et al., 2006b; Lin and
Emerman, 2006). To examine the role of the different TRIMCyp
domains in the restriction of FIV infection, we stably expressed
a previously described set of TRIMCyp variants with different
N-terminal deletions in CRFK feline cells (Figs. 3A and B).
Deletion of the RING domain or RING and B-Box 2 domains of
TRIMCyp (TRIMCypΔ93 and TRIMCypΔ128, respectively)
did not affect the ability of the protein to restrict FIV infection
efficiently (Fig. 3C). In contrast, similar deletions partially
decreased the ability of the TRIMCyp protein to restrict HIV-1
and SIVagm infection (Figs. 3D and E).
Deletion of the TRIMCyp coiled coil in the TRIMCypΔ245
and TRIMCypΔ310 mutants resulted in the complete elimination
of FIV-restricting ability (Fig. 3C). These mutants exhibited weak
inhibitory activity against HIV-1 and SIVagm (Figs. 3D and E).
Thus, as has been previously observed (Diaz-Griffero et al.,
2006b; Hatziioannou et al., 2005; Yin et al., 1998), over-
expression of cyclophilin A-like proteins can result in decreased
susceptibility of cells to HIV-1.
Fig. 4. FIV restriction by TRIM5αrh. CRFK cells expressing the indicated wild-
type and mutant TRIM5αrh proteins (A, B) were challenged with FIV–GFP (C).
GFP-positive cells were counted. Similar results were obtained in three
independent experiments.
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FIV infection is also potently blocked by TRIM5αrh (Saenz
et al., 2005). To examine if FIV restriction requires the
TRIM5αrh RING and B-box 2 domains, we expressed wild-
type TRIM5αrh and TRIM5αrh mutants with N-terminal
deletions in CRFK feline cells (Figs. 4A and B). The cells
were challenged with FIV (Fig. 4C). In contrast to the results
obtained for TRIMCyp, deletions of the RING and B-box 2
domains dramatically attenuated the ability of TRIM5αrh to
inhibit FIV infection.
TRIM5αrh potency against FIV maps to the V1 region of the
B30.2 domain
The TRIM5α B30.2 domain determines the specificity of
recognition of the targeted retroviral capsid (Saenz et al., 2005;Fig. 3. FIV restriction by TRIMCyp variants. CRFK cells were transduced with
either the empty LPCX vector or an LPCX vector expressing wild-type
TRIMCyp or the TRIMCyp mutants shown in A. Cell lysates were analyzed by
Western blot using antibodies against HA (upper panel) andβ-actin (lower panel)
(B). CRFK cells expressing the different TRIMCyp variants were challenged
with FIV–GFP (C), HIV-1–GFP (D) or SIVagm–GFP (E). GFP-positive cells
were counted by flow cytometry. Similar results were obtained in three inde-
pendent experiments.
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of the B30.2 domain of TRIM5αrh is the major determinant of
anti-HIV-1 potency (Li et al., 2006; Perez-Caballero et al., 2005a;
Stremlau et al., 2005;Yap et al., 2005). Sequences in the v1 and v3
regions of the TRIM5αhu B30.2 domain contribute to efficient N-
MLV restriction (Perron et al., 2006). To investigate the TRIM5α
determinants of potency for FIV restriction, we took advantage of
the observation that TRIM5αrh efficiently restricts FIV infection,
whereas TRIM5αhu only weakly inhibits FIV infection. Protein
chimerae containing different segments of TRIM5αrh and
TRIM5αhu (Stremlau et al., 2005) were expressed in CRFK
cells (Figs. 5A and B). The chimeric proteins all formed trimers
(see Fig. 7 below). A chimeric protein (H(R286–371)), in which
TRIM5αhu amino acids 286–371 have been replaced by the
equivalent sequences of TRIM5αrh, inhibited FIV infection
comparably to TRIM5αrh (Fig. 5C). The reciprocal construct, R
(H286–371), in which a B30.2(SPRY) domain segment span-Fig. 5. TRIM5αrh potency against FIV maps to the v1 region of the B30.2 domain. CR
proteins (A) were Western blotted with an antibody directed against the HA epitope
(C). GFP-positive cells were counted. Similar results were obtained in three indepenning the v1 region of TRIM5αrh has been replaced by that of
TRIM5αhu, exhibited no inhibition of FIVinfection. These results
suggest that the B30.2(SPRY) domain segment that includes the
v1 variable region determines the potency of FIV restriction.
Effects of changes in the TRIM5α B30.2 domain v1 region on
retrovirus restriction
The effects of deletions in the B30.2 domain v1 region on
retroviral restriction by TRIM5αrh were examined. TRIM5αrh
mutants with deletions affecting different segments of the B30.2
v1 region (Fig. 6A) were stably expressed in CRFK cells
(Fig. 6B). The cells were challenged with recombinant HIV-1,
EIAV and FIV expressing GFP (Figs. 6C–E). A short deletion
(Δ333–339) in the middle of the v1 variable region exerted only
minimal effects on the ability of TRIM5αrh to restrict these three
retroviruses, even though the expression level of the mutantFK cells expressing the indicated wild-type and TRIM5αrh–TRIM5αhu chimeric
tag and control anti-β-actin antibody (B). Cells were challenged with FIV–GFP
dent experiments.
Fig. 6. Effects of changes in the TRIM5αrh and TRIM5αhu B30.2 domain v1 region on restriction of HIV-1, EIAVand FIV. (A) Wild-type TRIM5αrh and TRIM5αhu
and the indicated mutants were expressed in CRFK cells. Cells were lysed and Western blotted with an anti-HA antibody or a control antibody directed against β-actin
(B). Cells were challenged with recombinant HIV-1 (C), EIAV (D) or FIV (E, G) expressing GFP. GFP-positive cells were counted. Similar results were obtained in a
repeat experiment. (F) Cell lysates containing the indicated TRIM5αrh variants were incubated with HIV-1 CA–NC complexes. The mixtures were layered on a 70%
sucrose cushion and centrifuged. The input lysates and pellets were Western blotted with an antibody directed against the TRIM5αrh HA epitope tag. The pellets were
also Western blotted with an anti-p24 CA antibody.
405F. Diaz-Griffero et al. / Virology 369 (2007) 400–410
Fig. 7. Oligomerization of TRIM5α variants. 293T cells were transiently transfected with plasmids expressing TRIM5α variants. Cells were lysed 48 h after
transfection and cross-linked with the indicated concentrations of ethylene glycol-bis(succinimidyl succinate) (EGS) as described in Materials and methods. The cell
lysates were subsequently blotted with an anti-HA antibody.
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344) in the B30.2 v1 region significantly decreased TRIM5αrh
restricting activity. Intermediate levels of restriction were
observed for proteins [TRIM5αrh (Δ323–332) and TRIM5αrh
(Δ332–344)] with deletions affecting the flanks of the B30.2 v1
region. A deletion of the B30.2 v3 region (Δ403–440)
eliminated detectable restricting activity of TRIM5αrh without
affecting the oligomerization state of the protein (Fig. 7). These
results support a role of the B30.2 variable regions in the
restriction of HIV-1, EIAV and FIV infection.
To investigate the mechanism by which B30.2 v1 region
deletions affect restricting activity, the ability of the TRIM5αrh
mutants to bind HIV-1 capsid–nucleocapsid (CA–NC) com-
plexes was examined (Fig. 6F). The wild-type TRIM5αrh
protein and the potent restriction factor TRIM5αrh Δ(333–339)
efficiently associated with HIV-1 CA–NC complexes. The other
TRIM5αrh mutants tested bound much less efficiently to the
HIV-1 CA–NC preparations. Thus, decreased ability to bind the
HIV-1 capsids contributes to the diminished HIV-1-restricting
activity of TRIM5αrh mutants with deletions affecting the B30.2
(SPRY) v1 region.
Changes in a single residue, arginine 332, within the B30.2 v1
region of TRIM5αhu can create a potent restrictor of HIV-1
infection (Stremlau et al., 2005; Yap et al., 2005; Li et al., 2006).
To examine whether this residue affects the ability of TRIM5αhu
to inhibit FIV infection, cells expressing TRIM5αhu R332P were
challengedwith FIV–GFP. Fig. 6G shows that TRIM5αhu R332P
inhibited FIV infection comparably to the wild-type TRIM5αhu
protein. The H(R323–332) protein, a TRIM5αhu variant that
contains residues 323–332 from TRIM5αrh (Fig. 6A), restricted
FIV infection more efficiently than the wild-type TRIM5αhu
protein. Thus, the determinants of TRIM5α potency for therestriction of HIV-1 and FIV infection are closely related but not
identical, and include the v1 region of the B30.2(SPRY) domain.
Oligomerization of TRIM5α variants
TRIM5α assembles into trimers, a property that contributes
to its ability to bind HIV-1 capsids and to restrict retroviral
infection (Mische et al., 2005; Javanbakht et al., 2006). To
examine the oligomerization of the TRIM5α variants studied
herein, lysates from cells expressing these proteins were cross-
linked and analyzed (Fig. 7). All of the TRIM5α proteins
examined formed trimers.
Discussion
The steady-state level of capsid protein in the cytosol of HIV-
1-infected cells is determined by the amount of capsid entering
the cell and the amount of capsid protein undergoing degra-
dation. The total levels of HIV-1 capsid protein were similar
in the cytosol of infected control cells and cells expressing
TRIMCyp or TRIM5αrh. This observation is consistent with a
minimal effect of TRIMCyp or TRIM5αrh on HIV-1 entry or
capsid turnover.
Compared with those in control cells, the levels of particulate
cytosolic HIV-1 capsids in TRIMCyp- or TRIM5αrh-expressing
cells were decreased. The results observed herein are consistent
with previously described models in which restriction factors
promote the premature uncoating of the incoming retroviral
capsid (Perron et al., 2007; Stremlau et al., 2006). Despite
differences in the capsid-binding moieties of TRIMCyp and
TRIM5α, the ultimate consequences of binding these factors to
the HIV-1 capsid appear to be remarkably similar.
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2 domains for the function of TRIMCyp and TRIM5αrh.
Deletion of these domains from TRIM5αrh eliminated detectable
restricting activity directed against HIV-1 and FIV, consistent
with previous observations (Diaz-Griffero et al., 2007; Yap et al.,
2007; Perez-Caballero et al., 2005a,b; Javanbakht et al., 2005).
By contrast, a TRIMCyp variant lacking the RING and B-box 2
domains exhibited partial ability to block HIV-1 and SIVagm
infection. Moreover, RING- and B-box-2-deleted TRIMCyp
fully restricted FIV. In a separate study (Javanbakht et al., 2007),
oligomerization of the cyclophilin A domain and L2 linker of
TRIMCyp with a heterologous multimeric motif was shown to
be sufficient to create an efficient HIV-1- and FIV-restricting
factor. Cyclophilin A oligomerization results in increased
avidity for the HIV-1 capsid (Diaz-Griffero et al., 2006b;
Javanbakht et al., 2007). These observations suggest a model in
which increased cyclophilin A occupancy of the HIV-1 capsid
results in inhibition of infection. The prolyl isomerase activity of
the bound cyclophilin Amay alter the conformation of the HIV-1
capsid protein and thereby modulate the uncoating process.
TRIM5α, by contrast, has no such prolyl isomerase activity and
thus may be more dependent on a B-box-2-directed function for
restriction-related capsid uncoating. For example, the TRIM5α
B-box 2 may recruit host cell uncoating factor(s) that contribute
to restriction.
We also noted that FIVappears to be restricted by RING- and
B-box-2-deleted TRIMCyp and artificially oligomerized cyclo-
philin A constructs more effectively than HIV-1 or SIVagm. The
FIV capsidmay bind cyclophilin Amore tightly, may intrinsically
differ in stability from the HIV-1 and SIVagm capsids, or may be
more susceptible to the effects of cyclophilin A binding or activity
on the uncoating process. Future studies should clarify the basis
for these differences in sensitivity to restriction.
HIV-1-infected cells treated with proteasome inhibitors
exhibited large increases in the amount of particulate, cytosolic
capsids, regardless of TRIM5αrh or TRIMCyp expression. Under
these conditions, differences between the amounts of particulate
capsids in the cytosol of cells expressing TRIM5αrh/TRIMCyp or
control cells were obscured. Particulate HIV-1 capsids also
persisted in the cytosol of cells expressing TRIMCyp mutants
with altered B-box 2 domains, even though these mutants still
inhibited HIV-1 infection. Thus, some level of restriction can be
observed even when particulate capsid can still be detected in the
cytosol of infected cells. This may reflect differences in the
sensitivity of the infectivity and fate-of-capsid assays; for
example, partially disrupted capsids may still pellet in the latter
assay even though their infectivity is markedly compromised.
Alternatively, other mechanisms of restriction may apply in the
circumstance of proteasome inhibition, which results in major
redistribution and coalescence of TRIM5α/TRIMCyp cytoplas-
mic aggregates. In future studies investigating these possibilities,
it will be important to document the relevance of the restrictive
mechanisms operative during proteasome inhibition to those
pertaining to TRIM5α/TRIMCyp under natural conditions.
The anti-FIV potency of TRIM5αrh is dependent on variable
region 1 of the B30.2 domain. This same region has been shown
to contribute to the ability of TRIM5αrh to restrict HIV-1 andTRIM5αhu to restrict N-MLV (Stremlau et al., 2005; Perron
et al., 2006). The variable regions have been suggested to be
surface-exposed loops on the B30.2(SPRY) domain, analogous
to the complementarity-determining loops of immunoglobulins.
Our results suggest that different TRIM5α proteins utilize
common structural motifs for the recognition of diverse
retroviral capsids. Future studies should shed light on the
mechanistic details of TRIM5α-capsid interaction.
Materials and methods
Plasmid construction
Plasmids expressing wild-type and mutant variants of
TRIMCyp, TRIM5αrh and TRIM5αhu proteins tagged with a
carboxy-terminal hemagglutinin (HA) epitope were constructed
using PCR. The respective cDNA was PCR-amplified and
digested with EcoRI and ClaI, whose sites were introduced by
inclusion in each of the PCR primers. These fragments were
cloned into the EcoRI and ClaI sites of the pLPCX vector
(Stratagene). TRIM5αrh–TRIM5αhu chimeric proteins were
named as previously described (Stremlau et al., 2005). The
nomenclature for the chimerae is TRIM5 A(Bx–y), in which the
encoded TRIM5 amino acids from x to y from species B are
inserted into the TRIM5 protein of species A (H, human; R,
rhesus monkey). The numbering scheme is based on the human
TRIM5 residue numbers; the same numbers are used for the
rhesus monkey TRIM5 residues, based on the alignment of the
TRIM5rh sequence to that of TRIM5hu.
Cells
Cf2Th canine thymocytes were obtained from ATCC. Cat
CRFK cells were kindly provided by Dr. Eric Poeschla (Mayo
Clinic).
Creation of cells stably expressing TRIMCyp and TRIM5α
variants
Retroviral vectors encoding wild-type or mutant TRIMCyp
or TRIM5α proteins were created using the pLPCX vector.
Recombinant viruses were produced in 293T cells by
cotransfecting the pLPCX plasmids with the pVPack-GP and
pVPack-VSV-G packaging plasmids (Stratagene). The pVPack-
VSV-G plasmid encodes the vesicular stomatitis virus (VSV) G
envelope glycoprotein, which allows efficient entry into a wide
range of vertebrate cells. Transduced cells were selected in 1 μg/
ml puromycin (Sigma).
Infection with viruses expressing green fluorescent protein (GFP)
Recombinant HIV-1 and SIVagm expressing GFP were
prepared as described (Stremlau et al., 2004). Viral stocks were
quantified by measuring reverse transcriptase (RT) activity. For
infections, 3×104 CRFK cells seeded in 24-well plates were
incubated with virus for 24 h. Cells were washed and returned to
culture for 48 h, and then subjected to FACS analysis with a
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virus (FIV) vector was obtained from System Biosciences
(Mountain View, CA) and was prepared following the manufac-
turer's instructions.
Protein analysis
Cellular proteins were extracted with radioimmunoprecipita-
tion assay (RIPA) buffer (10 mM Tris, pH 7.4; 100 mM NaCl;
1% sodium deoxycholate; 0.1% sodium dodecyl sulfate [SDS];
1% NP40; 2 mg/ml aprotinin; 2 mg/ml leupeptin; 1 mg/ml
pepstatin A; 100 mg/ml phenylmethylsulfonyl fluoride). The
cell lysates were analyzed by SDS–PAGE (10% acrylamide),
followed by blotting onto nitrocellulose membranes (Amersham
Pharmacia Biotech). Detection of protein by Western blotting
utilized monoclonal antibodies directed against the HA (Roche)
epitope tag, and monoclonal antibodies to β-actin (Sigma).
Detection of proteins with HA epitope tags was performed by
enhanced chemiluminescence (NEN Life Sciences Products),
using an anti-rat HRP secondary antibody (Amersham Pharma-
cia Biotech).
Fate-of-capsid assay
Cf2Th or CRFK cells were seeded on T80 plates at 20%
confluence one day before the experiments. Cells were
incubated with 10 ml of HIV-1 VLPs with or without envelope
glycoproteins at 4 °C for 30 min. The cultures were then shifted
to 37 °C and harvested at the indicated times. Samples were
processed as previously described (Stremlau et al., 2006).
Briefly, cells were lysed in a detergent-free buffer. After low-
speed centrifugation to pellet nuclei and cell debris, the cytosolic
extracts (“Input”) were layered onto a 50% sucrose cushion.
After centrifugation, the “Pellet” was resuspended in 1× loading
buffer and analyzed together with the “Input” by Western blot
with a monoclonal antibody against the HIV-1 p24 capsid
protein.
HIV CA–NC expression and purification
The HIV-1 CA–NC protein was expressed, purified and
assembled as previously described (Ganser et al., 1999). The
pET11a expression vector (Novagen) expressing CA–NC of
HIV-1 was used to transform BL-21(DE3). CA–NC expression
was induced with 1 mM isopropyl-beta-D-thiogalactopyranoside
(IPTG) when cells achieved an optical density at 600 nm of 0.6.
After 4 h of induction, cells were harvested and resuspended in
20 mM Tris–HCl (pH 7.5), 1 μM ZnCl2, 10 mM 2-merca-
ptoethanol and protease inhibitors (Roche). Bacteria were lysed
by sonication and debris was pelleted for 30 min at 35,000 ×g.
Nucleic acids were stripped from the solution by using 0.11
equivalents of 2 M (NH4)2SO4 and the same volume of 10%
polyethylenimine. Nucleic acids were removed by stirring and
centrifugation at 29,500×g for 15 min. Protein was recovered by
addition of 0.35 equivalents of saturated (NH4)2SO4. Protein was
centrifuged at 9820×g for 15 min and resuspended in 100 mM
NaCl, 20 mM Tris–HCl (pH 7.5), 1 μM ZnCl2 and 10 mM 2-mercaptoethanol. Protein was dialyzed against 50 mM NaCl,
20 mM Tris–HCl (pH 7.5), 1 μM ZnCl2 and 10 mM 2-
mercaptoethanol.
In vitro assembly of HIV-1 capsid complexes
HIV-1 capsid complexes were assembled in vitro by diluting
the HIV-1 CA–NC protein to a concentration of 0.3 mM in
50 mM Tris–HCl (pH 8.0), 0.5 M NaCl and 2 mg/ml DNA
oligo (TG)50. The mixture was incubated at 4 °C overnight and
centrifuged at 8600×g for 5 min. The pellet was resuspended in
assembly buffer (50 mM Tris–HCl (pH 8.0), 0.5 M NaCl) at a
final protein concentration of 0.15 mM (Ganser-Pornillos et al.,
2004).
TRIM5 variants binding to HIV-1 CA–NC complexes
293T cells were transfected with plasmids expressing
different TRIMCyp or TRIM5 proteins. Forty-eight hours
after transfection, cell lysates were prepared as follows: Washed
cells were resuspended in hypotonic lysis buffer (10 mM Tris,
pH 7.4, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT). The cell
suspension was frozen and thawed, and then incubated on ice
for 10 min. Afterwards, the lysate was centrifuged at 14,000×g
in a refrigerated microcentrifuge for 5 min. The supernatant was
supplemented with 1/10 volume of 10× PBS and then used in
the binding assay. Five ml of in vitro assembled CA particles
were incubated with 200 μl of cell lysate at room temperature for
1 h. A fraction of this mixture was stored (Input). The remainder
of the mixture was spun through a 70% sucrose cushion (70%
sucrose, 1× PBS and 0.5 mM DTT) at 100,000×g in an SW55
rotor (Beckman) for 1 h at 4 °C. After centrifugation, the
supernatant was carefully removed and the pellet was
resuspended in 1× SDS–PAGE loading buffer (Pellet). The
level of TRIM5 proteins was determined by Western blot.
Cross-linking of TRIM5 variants
The HA-tagged proteins were expressed transiently in 293T
cells. Cells were washed in phosphate-buffered saline (PBS)
and lysed in NP40 lysis buffer (0.5% Nonidet P40 (NP40), 1×
protease inhibitor (complete EDTA-free, Roche Diagnostics) in
PBS) for 45 min at 4 °C. Lysates were centrifuged at 14,000×g
for 15 min at 4 °C. The cleared lysates were not stored or frozen,
but rather were directly cross-linked. Approximately 100–
200 μl of cleared lysates were diluted with PBS/1 mM EDTA to
a final volume of 400 μl. Lysates were cross-linked with varying
concentrations (up to 10 mM) of ethylene glycol-bis(succini-
midyl succinate) (EGS) for 30 min at room temperature and
centrifuged briefly in a table-top centrifuge. The reaction mix
was quenched with 0.1 M Tris–HCl, pH 7.5, and briefly
centrifuged. The cleared, cross-linked lysates were precipitated
with the anti-HA antibody HA.11 (Covance) and protein A-
Sepharose beads (Amersham) for 2 h at 4 °C; final volumes for
the immunoprecipitation were greater than 700 μl. The beads
were washed four times with NP40 wash buffer (10 mM Tris–
HCl, pH 7.5, 0.5 M NaCl, 0.5% NP40) and boiled in LDS
409F. Diaz-Griffero et al. / Virology 369 (2007) 400–410sample buffer (106 mM Tris–HCl, 141 mM Tris Base, pH 8.5,
0.51 mM EDTA, 10% glycerol, 2% LDS, 0.22 mM SERVA
Blue G250, 0.175 mM phenol red (Invitrogen)) with a final
concentration of 1.2% β-mercaptoethanol (β-ME) for 10 min.
Precipitated proteins were separated on 8% or 12% Tris–
glycine gels, transferred to a PVDF membrane, and detected
with the horseradish peroxidase-conjugated 3F10 anti-HA
antibody (Roche Diagnostics) and the ECL Plus Western
Blotting Detection System (Amersham).
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